Combining high-throughput CRISPR with in silico cancer drug development
In my last post I wrote about a computational screen of TCGA data and its use in repurposing approved drugs and/or finding new drug candidates for cancer patients. The work demonstrated the possibilities for finding novel treatments, but I also pointed to a cautionary Vemurafenib […]



